A small molecule derived from the spacer domain of the tumor-suppressor gene Rb2/p130 has demonstrated the ability to inhibit tumor growth in vivo and could be developed into an anti-cancer therapeutic, according to researchers at Temple University's Sbarro Institute for Cancer Research and Molecular Medicine.
The researchers reported their findings, "A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo," in the March 22 issue of the journal
Oncogene (
http://www.nature.com/onc). Rb2/p130 was discovered in the early 1990s by Antonio Giordano, director of the Sbarro Institute and the Center for Biotechnology in Temple's College of Science and Technology, who headed the study.
The researchers discovered that within Rb2/p130's spacer domain--a sequence of 212 amino acids located in the pocket or middle section of the gene--was a small portion that resembled an amino-acidic sequence contained in the protein p21, which acts as a cdk (cyclin dependent kinase) inhibitor. Cdks play a critical role in cell cycle regulation.
"What we tested was the ability of the Rb2/p130 spacer region to inhibit the kinase activity of cdk2, which is the same kinase p21 inhibits," said Giordano, one of the study's lead authors. "And to our surprise, it happened." The researchers then set about trying to reduce the spacer domain's 212 amino acids down to the smallest sequence that would still produce the same functionality as p21, explained Giordano.
"We thought we could narrow down the spacer region that contains the protein-like motif to a small portion that could be delivered as a small molecule or peptide," Giordano said.
They discovered a 39 amino-acid-long sequence, which they named Spa310. The molecule that was synthetically produced in the laboratory was introduced into mice that had been injected with tumor cells.
"Tumor growth was inhibited and the tumors began to reduce in size until they disappeared," Giordano said.
Giordano said because of the intrinsic nature of the compound, it can be easily reproduced as a biological drug in large quantities and does not require potentially dangerous means of delivery like viruses, as do most gene therapies; therefore Spa310 has a good chance to succeed as an anti-cancer therapy. For these reasons, he believes it may be easier to get approval for clinical trials.
"Fifteen years after discovering Rb2/p130, our research and hard work has led us to the discovery of this small molecule, which is a step forward in cancer research and a big step toward a cancer treatment," he said.
Source: Temple University
Related stories:
Progress Toward an Antitumor Vaccine
How can we induce the body to use its own weapon, the immune system, to battle cancer?
Single-Molecule Chemical-Field-Effect Transistor with Nanometer-Sized Gates
F. Jackel and group of scientists from Max-Planck-Institute and Humboldt University Berlin, Germany present a prototypical single-molecule chemical-field-effect transistor, in which the current through a hybrid-molecular diode is modified by nanometer-sized charge transfer complexes covalently linked to a molecule in an STM junction. Their article is published in the last
Physical Review Letters issue ( vol. 92, no. 18 )
Gold Nanostars Outshine the Competition
(PhysOrg.com) -- Novel nanoparticles being tested at the National Institute of Standards and Technology have researchers seeing stars. In a recent paper,* NIST scientists used surface-enhanced Raman spectroscopy (SERS) to demonstrate that gold nanostars exhibit optical qualities that make them superior for chemical and biological sensing and imaging. These uniquely shaped nanoparticles may one day be used in a range of applications from disease diagnostics to contraband identification.
Scientists close in on method to fight deadly childhood cancer
A multicenter team of researchers, including scientists from the University of Florida, has discovered a way to potentially block the growth of neuroblastoma, a type of cancer responsible for 15 percent of all cancer deaths in children.
Brain-nourishing molecule may predict schizophrenia relapse
A factor that helps optimize brain formation and function may also provide clues about whether patients suffering with schizophrenia are headed toward relapse, researchers say.
Teaching Nano to Swim
(PhysOrg.com) -- Ayusman Sen, head of the Department of Chemistry at Penn State, makes tiny, metallic objects do something extraordinary -- he makes them swim. Sen's work is driven by catalysis, the chemical phenomenon whereby a substance accelerates a chemical reaction but emerges unchanged at the end of the process.
Worms' nervous system shown to alert immune system in Stanford studies
The nervous system and the immune system have something in common. Each has evolved to react quickly to environmental cues. Because the nervous system is able to detect some of these cues - say, a characteristic odor signaling a pathogen's presence - at a distance, it sometimes can sense trouble earlier than the immune system, which has to wait until the pathogen invades the organism.
Smell is 'noisy' and 'in shades of grey': Scientists debunk ancient lock-and-key theory
University of Manchester scientists have overturned the 2,500-year-old theory that smell is detected by simple lock-and-key codes – using maggots with only one working olfactory sensory neuron (OSN), a nose with one nerve cell.